The US Food and Drug Administration is aware of the difficulties of getting approval of rare disease treatments, Commissioner Robert Califf said, and the agency needs stakeholders help to develop creative approaches to overcome them.
Califf gave a closing keynote address at a recent conference sponsored by the New York University Grossman School of Medicine...